Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018
April 09 2018 - 9:01AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its
financial results for the fourth quarter and fiscal year ended 31
January 2018 on 11 April 2018.
Summit will host a conference call and webcast
the same day to discuss its operational progress at 1:00pm BST /
8:00am EDT. Conference call and webcast information will be
included in the full year results press release. A replay of the
call will also be available through the Company's website,
www.summitplc.com, shortly after its conclusion.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit |
|
|
Glyn Edwards
/ Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Erik Ostrowski /
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
Tel: |
+44 (0)20 7213
0880 |
Liam Murray / Tony
Rawlinson |
|
|
|
|
|
N+1
Singer (Joint Broker) |
Tel: |
+44 (0)20 7496
3000 |
Aubrey Powell / Jen
Boorer |
|
|
|
|
|
Panmure
Gordon (Joint Broker) |
Tel: |
+44 (0)20 7886
2500 |
Freddy Crossley,
Corporate Finance |
|
|
Tom Salvesen, Corporate
Broking |
|
|
|
|
|
MacDougall
Biomedical Communications (US) |
Tel: |
+1 781 235 3060 |
Karen Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (UK) |
Tel: |
+44 (0)20 3709
5700 |
Mary-Jane Elliott /
Jessica Hodgson / |
|
summit@consilium-comms.com |
Philippa Gardner /
Rosie Phillips |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024